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404a Tuesday, February 5, 2013azido-modified aromatic drug molecules can keep their original pharmacolog-
ical activity. By photoactivating of such modified molecules in vivo, both
their strong and weak partners can be captured. Moreover, applying the azi-
dated drug in a concentration range and utilizing proteomic tools the apparent
binding constants of protein-ligand interactions can be determined.
We have developed a new and simple technique to azidate aromatic drug mol-
ecules in an easy two step reaction. Using our method we have synthesized
azidoblebbistatin which is a new derivative of blebbistatin, the most widely
used myosin inhibitor. In the absence of UV irradiation azidoblebbistatin
and blebbistatin exhibits identical inhibitory properties. Using UV light azido-
blebbistatin can be covalently crosslinked to myosin whereas the unbound in-
hibitor molecules become inactive. Using Dictyostelium discoideum cell
lysate we performed interactomic investigation to identify the previously un-
known targets of blebbistatin utilizing the self- fluorescence of azidoblebbista-
tin. Since the crosslinking was performed applying increasing concentration of
azidoblebbistatin, densitometry of the fluorescent spots resulting from gelelec-
trophoresis revealed the apparent binding constant of azidoblebbistatin. In case
of myosin II it was the exact value as measured in in vitro tests. With this tech-
nique the strongest interactant was found to be myosin II (EC50=5 mM) while
eight weak partners (EC50>30 mM) were also detected including vacuolar
Hþ-ATPase (EC50=50 5 31 mM), malate dehydrogenase (EC50=55 5
17 mM) and elongation factor 1a (EC50>100 mM).
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Plasmodium falciparum is the parasite responsible for the most deadly cases of
malaria. Emerging drug resistance to current therapies requires research to de-
velop new antimalarials. A potential target of new drugs is the proteolytic
egress cascade, which has been identified as essential to the blood stage para-
site. A key protein in the cascade is subtilisin-like protease 1 (SUB1). This pro-
tease undergoes two self-cleavage events to separate the N-terminal
prodomain, necessary for correct folding, from the C-terminal, catalytic do-
main. To obtain protein suitable for crystallization, we have expressed SUB1
both in bacterial and insect cell systems. However, recovery is difficult and
yield is often low. To improve the yield and purity of the protein, we employ
a selective affinity purification scheme developed in the lab. Our SPR valida-
tion assays indicate specific binding of a protein originating from either insect
cell or bacterial expression of recombinant SUB1. The possibility of producing
active SUB1 in bacterial systems after undergoing limited proteolysis is also
being explored and validated via SPR analysis. Determining dissociation con-
ditions and residues important to the interaction via mutational studies will pro-
vide a more comprehensive understanding of this protease and aid in future
structure based drug design.
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Pseudomonas aeruginosa (PA) is an opportunistic pathogen that causes lung in-
fections in cystic fibrosis and other immune-compromised individuals. The
most toxic factor secreted by PA is a 66 kDa protein, exotoxin A (ExoA), which
belongs to a larger (mART) family of enzymes that catalyze the transfer of the
ADP-ribosyl moiety from NADþ to a protein target.
COMPUTATIONAL APPROACH: Here, we used the high resolution crystal
structure of cholix as the structural model system for ExoA. We considered
structures in complex with several ligands (NADþ and various inhibitors:
NAP, V30, etc.) in order to address the mode of ligand binding. All the anal-
yses were performed with the Molecular Operative Environment suite
(MOE.2011). For each residue in the pocket, the interaction energy was eval-
uated along with various other descriptors. Binding free energy was calcu-
lated according to the GBVI/WSA function. Based upon the consensus
features of the cholix:ligand complexes, a pharmacophore model was devel-
oped and was used to dock these molecules as standards for the purpose of
training, followed by the docking of a new inhibitor library (M-series) ob-
tained from an in silico screening against another mART toxin, Iota toxin
from C. perfringens.
EXPERIMENTAL APPROACH: A cell based assay was used for a coarse
screen of the potency of the M-series inhibitors based on the viability of C38
cystic fibrosis human lung cells treated with ExoA. Compound M19 arose asthe best inhibitor for protection of the cystic fibrosis human lung cell line
with an EC50 of 2 mM. Future research will involve improvement of the
M19 scaffold based on the information from computational approaches.
This work was funded by a Cystic Fibrosis Canada (CFC) summer studentship
to AP, a CFC Canada-Kin postdoctoral fellowship to MRL, and CFC operating
grant to ARM.
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Dengue viruses (DENV) are transmitted by mosquitoes and infect ~50 million
people annually with an additional 2.5 billion people at risk living in tropical
areas. However, there are no approved vaccines or antiviral therapies to combat
the disease. DENV genome is translates into a single polyprotein comprising 3
structural and 7 non-structural (NS) proteins. The polyprotein precursor is
cleaved by both host proteases and the two-component virus protease NS2B-
NS3. Thus, this protease is considered as a promising target for antiviral design.
In order to identify novel inhibitors of the DENV NS2B-NS3 protease we fo-
cused our strategy on the allosteric inhibitors capable of targeting the NS2B-
NS3 interaction rather than the NS3 active site. The computational protocol
was performed for 7,240- FDA-approved drugs retrieved from the ZINC data-
base. We firstly implement a structure-based virtual screening to identify a pre-
liminary set of inhibitors against the catalytic domain in active form of DENV
NS2B-NS3 by docking analysis. The preliminary set inhibitors was then used to
perform a consensus scoring of docking poses, based on scoring functions from
the DrugScore and Xscore packages. Six docked poses were ranked among the
top 50 compounds according to consensus scoring and were used to molecular
dynamics (MD) simulation and free-energy calculation. Three compounds be-
longing to the piperazine derivatives family were finally proposed as potential
inhibitors for DENV NS2B-NS3. These compounds target the allosteric-
binding site of protease so that compound binding produces a conformational
change able to affect the interaction among the protease and peptide substrates.
The computational drug discovery strategy employed in our study could be ap-
plied for the identification of inhibitors of other flaviviral proteases.
2078-Pos Board B97
Specificity Quantification of Biomolecular Recognition and its Implication
for Drug Discovery
Zhiqiang Yan, Jin Wang.
Stony Brook University, Stony Brook, NY, USA.
Highly efficient and specific biomolecular recognition requires both affinity and
specificity. The stability of the complex is determined by the affinity while the
specificity is controlled by either partner binding to other competitive biomole-
cules discriminatively. Previous quantitative descriptions of biomolecular recog-
nition were mostly driven by improving the affinity prediction, but lack of
quantification of specificity. We developed a novel method SPA (SPecificity
and Affinity) based on our funneled energy landscape theory. The strategy is
to simultaneously optimize the quantified specificity of the ‘‘native’’ protein-
ligand complex discriminating against ‘‘non-native’’ binding modes and the af-
finity prediction. The benchmark testing of SPA shows the best performance
against 16 other popular scoring functions in industry and academia on both pre-
diction of binding affinity and ‘‘native’’ binding pose. For the target COX-2 of
nonsteroidal anti-inflammatory drugs, SPA
successfully discriminates the drugs from
the diversity set, and the selective drugs
from non-selective drugs. The remarkable
performance demonstrates that SPA has sig-
nificant potential applications in identifying
lead compounds for drug discovery.2079-Pos Board B98
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With a rapid increase in the number of high-resolution protein-ligand struc-
tures, the known protein-ligand structures can be used to gain insights into
how a ligand binds in a target protein. Based on the fact that the structurally
similar binding sites share information about their ligands, we have developed
a local structure alignment tool, G-LoSA (Graph-based Local Structure Align-
ment). Using G-LoSA, the known protein-ligand binding-site structure library
